Market Overview

CRO Industry Veteran John Potthoff Joins SynteractHCR Board of Directors


a leading full-service contract research organization (CRO), announced
the appointment of industry veteran John Potthoff to its Board of
Directors, effective immediately. Potthoff draws on extensive
operational, business development and leadership experience derived
through his 25-year career dedicated to clinical development.

Potthoff is a founder and CEO of Elligo Health Research, a leading
clinical research infrastructure provider whose mission is to redefine
the clinical trial process. Prior to this, he served as CEO of Theorem
Clinical Research and COO of INC Research, having successfully
contributed to the impressive growth of both CROs. In 2000 he founded
and was CEO of Tanistry, a CNS focused CRO, which was acquired by INC
Research. He currently sits on the Board of Directors for Chesapeake IRB
and previously served as a member of the Board of Directors for Chiltern.

"I have had the pleasure of working directly with John in the past. He
is both a respected business leader and an experienced board member in
our industry," said Steve
, CEO of SynteractHCR. "Drawing on his years of experience as
a CRO executive, industry leader and now CEO of a company that
implements new approaches to clinical trial conduct, John will provide
fresh insights and counsel invaluable to SynteractHCR and our customers.
I am delighted John has agreed to join our Board."

"We have known John for over 10 years and have seen how he has played a
leadership role in building value at INC Research and Theorem," added
Ramsey Frank, partner and co-founder of Amulet Capital. "We welcome
John's addition to the board and are confident his industry acumen will
help us build on SynteractHCR's leading market position and continue to
advance the company's success."

About SynteractHCR

With 800 staff members across 21 countries, SynteractHCR is an
international full-service contract research organization with a
successful three-decade track
supporting biotechnology, medical device and pharmaceutical
companies in all phases of clinical development. SynteractHCR has
conducted Phase
I-IV studies
on six continents and in more than 60 countries,
offering broad therapeutic expertise, with notable depth in oncology,
immunotherapy, CNS and infectious disease, among other indications. With
its "Shared
Work – Shared Vision
" philosophy, SynteractHCR provides customized
services collaboratively and cost effectively, ensuring on-time delivery
of quality data to help bring tomorrow's treatments to patients.

View Comments and Join the Discussion!